Diabetic retinopathy is associated with visceral fat accumulation in Japanese type 2 diabetes mellitus patients

Metabolism: Clinical and Experimental

Volumn 59, Issue 3, 2010, Pages 314-319

  Anan, Futoshi ^a   Masaki, Takayuki ^b   Ito, Yuji ^a   Eto, Takahiko ^a   Umeno, Yoshikazu ^a   Eshima, Nobuoki ^b   Saikawa, Tetsunori ^c   Yoshimatsu, Hironobu ^b  

^a OITA RED CROSS HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOREACTIVE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAABDOMINAL FAT; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICUS; WAIST CIRCUMFERENCE;

ADIPOSITY; AGED; ANTHROPOMETRY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; FEMALE; HOMEOSTASIS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; URIC ACID;

EID: 76249088271     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.06.001     Document Type: Article

References (37)

1. Klein R., Klein B.E., Moss S.E., et al. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 117 (1999) 1487-1495
2. Rajala U., Pajunpää H., Koskela P., et al. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 23 (2000) 957-961
3. van Hecke M.V., Dekker J.M., Stehouwer C.D., et al. EURODIAB prospective complications study. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 28 (2005) 1383-1389
4. Juutilainen A., Lehto S., Ronnemaa T., et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 30 (2007) 292-299
5. Boyko E.J., Fujimoto W.Y., Leonetti D.L., et al. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 23 (2000) 465-471
6. Hayashi T., Boyko E.J., Leonetti D.L., et al. Visceral adiposity and the prevalence of hypertension in Japanese-Americans. Circulation 108 (2003) 1718-1723
7. Matsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 13 (1997) 313
8. Fujimoto W., Bergstrom R., Boyko E., et al. Visceral adiposity and incident coronary heart disease in Japanese-American men: the 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 22 (1999) 1808-1812
9. St-Pierre J., Lemieux I., and Vohl M.C. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 90 (2002) 15-18
10. Raji A., Seely E.W., Arky R.A., et al. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 86 (2001) 5366-5371
11. Gastaldelli A., Miyazaki Y., Pettiti M., et al. Metabolic effects of visceral fat accumulation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87 (2002) 5098-5103
12. Hadjadj S., Péan F., Gallois Y., et al. Genesis France-Belgium Study. Different patterns of insulin resistance in relatives of type 2 diabetic patients with retinopathy or nephropathy. Diabetes Care 27 (2004) 2661-2668
13. Parvanova A., Iliev I., Filipponi M., et al. Insulin resistance and proliferative retinopathy cross-sectional, case-control study in 115 patients with type 2 diabetes. J Clin Endorinol Metab 89 (2004) 4371-4376
14. Liao D., Sloan R.P., Cascio W.E., et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 21 (1998) 2116-2122
15. Davis M.D. Vitreous contraction in proliferative diabetic retinopathy. Arch Ophthalmol 74 (1965) 741-751
16. Mancia G., De Backer G., Dominiczak A., et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25 (2007) 1751-1762
17. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
18. Taniguchi A., Fukushima M., and Sakai M. Remnant-like particle cholesterol, triglyceride, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 23 (2000) 1766-1769
19. Yoshizumi T., Nakamura T., Yamane M., et al. Abdominal fat: standardized technique for measurement at CT. Radiology 211 (1999) 283-286
20. 40K. Int J Obes 12 (1988) 249-266
21. The Examination Committee of Criteria for "Obesity Disease" in Japan, Japan Society for the Study of Obesity. New criteria for "obesity disease" in Japan. Circ J 66 (2002) 987-992
22. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
23. Yudkin J.S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Diabetes Care 22 (1999) C25-C30
24. Kurioka S., Koshimura K., Murakami Y., et al. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 47 (2000) 77-81
25. van Leiden H.A., Dekker J.M., and Moll A.C. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 25 (2002) 1320-1325
26. Wong T.Y., Duncan B.B., and Golden S.H. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk in Communities Study. Invest Ophthalmol Vis Sci 45 (2004) 2949-2954
27. Aiello L.P., Avery R.L., and Arrigg P.G. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
28. Miyazawa-Hoshimoto S., Takahashi K., Bujo H., et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46 (2003) 1483-1488
29. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabete Metab Res Rev 18 (2002) S5-S9
30. Mittelman S.D., Van Citters G.W., and Kim S.P. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response. Diabetes 49 (2000) 2116-2125
31. Steinberg H.O., Chaker H., and Leaming R. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97 (1996) 2601-2610
32. Hu C.T., Chang K.C., Wu C.Y., and Chen H.I. Acute effects of nitric oxide blockade with l-NAME on arterial haemodynamics in the rat. Br J Pharmacol 122 (1997) 1237-1243
33. Indolfi C., Torella D., and Cavuto L. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103 (2001) 2980-2986
34. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Eng J Med 342 (2000) 381-389
35. Miyazaki Y., Mahankali A., and Matsuda M. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 1784-1791
36. Shen L.Q., Child A., Weber G.M., et al. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 126 (2008) 793-799
37. Aljada A., O'Connor L., Fu Y.Y., et al. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angiogenesis 11 (2008) 361-367